Akebia Therapeutics (AKBA) Financials

$3.03 +0.02 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$3.04 +0.02 (+0.50%)

As of 07:56 PM Eastern

Annual Income Statements for Akebia Therapeutics

This table shows Akebia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-69	-52	-94
Consolidated Net Income / (Loss)	-69	-52	-94
Net Income / (Loss) Continuing Operations	-69	-52	-94
Total Pre-Tax Income	-69	-52	-94
Total Operating Income	-50	-46	-81
Total Gross Profit	97	120	207
Total Revenue	160	195	292
Operating Revenue	160	195	292
Total Cost of Revenue	63	74	86
Operating Cost of Revenue	63	74	86
Total Operating Expenses	147	167	288
Selling, General & Admin Expense	107	100	139
Research & Development Expense	38	63	130
Other Operating Expenses / (Income)	3.22	3.24	3.18
Restructuring Charge	0.06	0.18	16
Total Other Income / (Expense), net	-19	-5.67	-13
Interest Expense	0.52	0.00	0.91
Interest & Investment Income	-18	-6.03	-16
Other Income / (Expense), net	-0.24	0.36	3.15
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	-	0.00
Basic Earnings per Share	($0.33)	($0.28)	($0.52)
Weighted Average Basic Shares Outstanding	210.95M	187.47M	182.78M
Diluted Earnings per Share	($0.33)	($0.28)	($0.52)
Weighted Average Diluted Shares Outstanding	210.95M	187.47M	182.78M
Weighted Average Basic & Diluted Shares Outstanding	236.23M	209.37M	184.25M

This table shows Akebia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-23	-20	-8.58	-18	0.61	-14	-11	-27	-6.07	-54
Consolidated Net Income / (Loss)	-23	-20	-8.58	-18	0.61	-14	-11	-27	-1.91	-54
Net Income / (Loss) Continuing Operations	-23	-20	-8.58	-18	0.61	-14	-11	-27	-1.91	-54
Total Pre-Tax Income	-23	-20	-8.58	-18	0.61	-14	-11	-27	-0.33	-55
Total Operating Income	-14	-13	-8.73	-15	1.37	-13	-9.00	-26	-4.87	-50
Total Gross Profit	26	23	27	21	38	24	39	20	112	10
Total Revenue	46	37	44	33	56	42	56	40	117	49
Operating Revenue	46	37	44	33	56	42	56	40	117	49
Total Cost of Revenue	20	14	17	12	19	18	17	20	5.58	38
Operating Cost of Revenue	20	14	17	12	19	18	17	20	5.58	38
Total Operating Expenses	40	36	35	36	36	37	48	45	109	61
Selling, General & Admin Expense	28	27	27	25	25	23	27	25	30	32
Research & Development Expense	12	8.49	7.65	9.73	9.87	13	20	20	76	28
Other Operating Expenses / (Income)	0.98	0.77	0.76	0.71	0.86	0.86	0.95	0.57	1.54	0.74
Total Other Income / (Expense), net	-8.50	-7.53	0.14	-3.05	-0.76	-1.45	-2.18	-1.28	-3.55	-4.86
Interest & Investment Income	-6.88	-6.66	-2.15	-2.50	-1.42	-1.41	-1.64	-1.56	-6.70	-3.95
Other Income / (Expense), net	-1.62	-0.87	2.29	-0.03	0.66	-0.04	-0.53	0.28	-	-
Basic Earnings per Share	($0.10)	($0.10)	($0.04)	($0.09)	$0.01	($0.08)	($0.06)	($0.15)	($0.04)	($0.29)
Weighted Average Basic Shares Outstanding	210.95M	210.35M	209.71M	204.96M	187.47M	188.31M	186.82M	184.77M	182.78M	183.88M
Diluted Earnings per Share	($0.10)	($0.10)	($0.04)	($0.09)	$0.01	($0.08)	($0.06)	($0.15)	($0.03)	($0.29)
Weighted Average Diluted Shares Outstanding	210.95M	210.35M	209.71M	204.96M	187.47M	188.31M	186.82M	184.77M	182.78M	183.88M
Weighted Average Basic & Diluted Shares Outstanding	236.23M	218.18M	210.29M	209.60M	209.37M	188.39M	188.31M	0.00	184.25M	183.96M

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	8.97	-49	-59
Net Cash From Operating Activities	-41	-23	-73
Net Cash From Continuing Operating Activities	-41	-23	-73
Net Income / (Loss) Continuing Operations	-69	-52	-94
Consolidated Net Income / (Loss)	-69	-52	-94
Depreciation Expense	1.46	1.59	1.65
Amortization Expense	40	40	36
Non-Cash Adjustments To Reconcile Net Income	25	8.18	52
Changes in Operating Assets and Liabilities, net	-38	-21	-68
Net Cash From Investing Activities	-0.03	0.00	-0.11
Net Cash From Continuing Investing Activities	-0.03	0.00	-0.11
Purchase of Property, Plant & Equipment	-0.03	0.00	-0.11
Net Cash From Financing Activities	50	-25	15
Net Cash From Continuing Financing Activities	50	-25	15
Repayment of Debt	-38	-32	-33
Issuance of Debt	45	0.00	-
Issuance of Common Equity	43	6.79	7.53
Other Financing Activities, net	0.39	0.00	40
Cash Interest Paid	5.04	6.06	6.76

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	18	-5.47	-2.46	-0.96	-3.60	-7.12	-4.37	-34	-55	0.87
Net Cash From Operating Activities	-4.47	-6.70	-10	-19	-2.31	-7.17	3.63	-18	-55	34
Net Cash From Continuing Operating Activities	-4.47	-6.70	-10	-19	-2.31	-7.17	3.63	-18	-55	34
Net Income / (Loss) Continuing Operations	-23	-20	-8.58	-18	0.61	-14	-11	-27	-6.07	-54
Consolidated Net Income / (Loss)	-23	-20	-8.58	-18	0.61	-14	-11	-27	-6.07	-54
Depreciation Expense	0.34	0.36	0.40	0.36	0.39	0.40	0.40	0.40	0.41	0.41
Amortization Expense	13	9.01	9.01	9.01	13	9.01	9.01	9.01	8.72	9.01
Non-Cash Adjustments To Reconcile Net Income	5.96	12	3.48	3.59	0.42	1.09	2.92	3.76	12	22
Changes in Operating Assets and Liabilities, net	-1.16	-7.66	-14	-14	-17	-3.17	2.48	-3.83	-70	57
Net Cash From Investing Activities	-0.00	-0.00	-0.03	0.00	-	-	-	0.00	-	-
Net Cash From Continuing Investing Activities	-0.00	-0.00	-0.03	0.00	-	-	-	0.00	-	-
Purchase of Property, Plant & Equipment	-0.00	-0.00	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	22	1.22	7.64	18	-1.29	0.05	-8.00	-16	-0.00	-33
Net Cash From Continuing Financing Activities	22	1.22	7.64	18	-1.29	0.05	-8.00	-16	-0.00	-33
Repayment of Debt	0.00	-0.52	-0.37	-37	-8.00	-	-8.00	-16	-	-33
Issuance of Common Equity	22	1.75	-	19	6.71	0.05	-	0.03	-0.00	0.06
Other Financing Activities, net	0.23	-	0.01	0.14	0.00	-	-	0.00	-	-

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	221	242	356
Total Current Assets	114	118	185
Cash & Equivalents	52	43	90
Accounts Receivable	34	39	40
Inventories, net	16	16	22
Prepaid Expenses	11	20	33
Plant, Property, & Equipment, net	2.20	3.63	5.21
Total Noncurrent Assets	105	120	166
Goodwill	59	59	59
Intangible Assets	0.00	36	72
Other Noncurrent Operating Assets	46	25	35
Total Liabilities & Shareholders' Equity	221	242	356
Total Liabilities	270	272	351
Total Current Liabilities	81	100	130
Short-Term Debt	0.00	18	32
Accounts Payable	15	15	18
Accrued Expenses	63	68	76
Other Current Liabilities	2.27	0.00	-
Total Noncurrent Liabilities	189	172	221
Long-Term Debt	39	17	34
Noncurrent Deferred Revenue	0.00	43	43
Other Noncurrent Operating Liabilities	150	112	144
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-49	-31	5.23
Total Preferred & Common Equity	-49	-31	5.23
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-49	-31	5.23
Common Stock	1,629	1,578	1,562
Retained Earnings	-1,678	-1,609	-1,557
Accumulated Other Comprehensive Income / (Loss)	0.01	0.01	0.01

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	207	220	225	235	254	281	436
Total Current Assets	100	112	113	110	118	121	238
Cash & Equivalents	34	39	42	47	54	0.00	145
Accounts Receivable	32	30	27	23	20	19	23
Inventories, net	20	24	26	18	21	20	40
Prepaid Expenses	13	19	19	22	24	25	30
Plant, Property, & Equipment, net	2.53	2.90	3.27	4.02	4.42	0.00	5.62
Total Noncurrent Assets	104	105	109	121	131	59	193
Goodwill	59	59	59	59	59	59	55
Intangible Assets	9.01	18	27	45	54	0.00	81
Other Noncurrent Operating Assets	36	28	23	17	18	0.00	57
Total Liabilities & Shareholders' Equity	207	220	225	235	254	281	436
Total Liabilities	258	254	253	274	281	300	422
Total Current Liabilities	66	107	66	80	92	88	188
Short-Term Debt	0.00	0.00	0.00	8.00	24	0.00	66
Accounts Payable	13	10	12	9.04	12	0.00	20
Accrued Expenses	52	54	54	63	56	51	87
Total Noncurrent Liabilities	192	147	186	195	188	17	234
Long-Term Debt	38	38	30	35	18	0.00	-
Noncurrent Deferred Revenue	0.00	0.00	43	43	43	0.00	43
Other Noncurrent Operating Liabilities	153	109	113	117	127	17	191
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-50	-34	-27	-39	-27	-1,584	14
Total Preferred & Common Equity	-50	-34	-27	-39	-27	-19	14
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-50	-34	-27	-39	-27	-1,584	14
Common Stock	1,605	1,602	1,600	1,570	1,568	0.00	1,559
Retained Earnings	-1,656	-1,636	-1,627	-1,610	-1,595	-1,584	-1,545
Accumulated Other Comprehensive Income / (Loss)	0.01	0.01	0.01	0.01	0.01	0.00	0.01

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-17.70%	-33.46%	38.19%
EBITDA Growth	-122.54%	89.94%	82.05%
EBIT Growth	-10.49%	40.88%	70.38%
NOPAT Growth	-9.11%	42.74%	69.46%
Net Income Growth	-33.67%	44.89%	66.59%
EPS Growth	-17.86%	46.15%	69.41%
Operating Cash Flow Growth	-73.88%	68.03%	71.08%
Free Cash Flow Firm Growth	7.21%	18.71%	88.12%
Invested Capital Growth	-60.62%	-102.66%	-188.08%
Revenue Q/Q Growth	-5.71%	-23.93%	25.66%
EBITDA Q/Q Growth	-232.36%	73.29%	61.14%
EBIT Q/Q Growth	-54.83%	12.58%	45.04%
NOPAT Q/Q Growth	-45.06%	11.89%	42.81%
Net Income Q/Q Growth	-50.91%	4.63%	41.90%
EPS Q/Q Growth	-50.00%	12.50%	41.57%
Operating Cash Flow Q/Q Growth	-5.61%	69.13%	10.00%
Free Cash Flow Firm Q/Q Growth	45.46%	78.22%	-132.06%
Invested Capital Q/Q Growth	-35.38%	10.41%	70.51%
Profitability Metrics	-	-	-
Gross Margin	60.56%	61.90%	70.74%
EBITDA Margin	-5.62%	-2.08%	-13.76%
Operating Margin	-31.51%	-23.77%	-27.62%
EBIT Margin	-31.66%	-23.58%	-26.54%
Profit (Net Income) Margin	-43.33%	-26.68%	-32.22%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	136.88%	113.14%	121.37%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-4,361.38%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-4,263.06%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	4,123.55%
Return on Equity (ROE)	174.03%	409.60%	-237.83%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-21.93%	-15.36%	-17.54%
Return on Assets (ROA)	-30.02%	-17.37%	-21.28%
Return on Common Equity (ROCE)	174.03%	409.60%	-237.83%
Return on Equity Simple (ROE_SIMPLE)	141.12%	169.78%	-1,801.64%
Net Operating Profit after Tax (NOPAT)	-35	-32	-57
NOPAT Margin	-22.06%	-16.64%	-19.33%
Net Nonoperating Expense Percent (NNEP)	-318.22%	-119.80%	-98.33%
Return On Investment Capital (ROIC_SIMPLE)	336.74%	-789.93%	-
Cost of Revenue to Revenue	39.44%	38.10%	29.26%
SG&A Expenses to Revenue	66.52%	51.50%	47.39%
R&D to Revenue	23.51%	32.41%	44.44%
Operating Expenses to Revenue	92.07%	85.67%	98.36%
Earnings before Interest and Taxes (EBIT)	-51	-46	-78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.01	-4.05	-40
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	20.30
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.59	1.20	0.36
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.51	1.16	0.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-0.79	-1.13	12.63
Long-Term Debt to Equity	-0.79	-0.56	6.52
Financial Leverage	0.27	1.29	-0.97
Leverage Ratio	-5.80	-23.58	11.17
Compound Leverage Factor	-7.93	-26.68	13.56
Debt to Total Capital	-368.79%	846.13%	92.67%
Short-Term Debt to Total Capital	0.00%	426.93%	44.88%
Long-Term Debt to Total Capital	-368.79%	419.20%	47.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	468.79%	-746.13%	7.33%
Debt to EBITDA	-4.30	-8.57	-1.64
Net Debt to EBITDA	1.46	2.04	0.61
Long-Term Debt to EBITDA	-4.30	-4.25	-0.85
Debt to NOPAT	-1.10	-1.07	-1.17
Net Debt to NOPAT	0.37	0.25	0.43
Long-Term Debt to NOPAT	-1.10	-0.53	-0.60
Altman Z-Score	-9.58	-8.54	-5.65
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.41	1.18	1.43
Quick Ratio	1.07	0.82	1.01
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-12	-13	-16
Operating Cash Flow to CapEx	-123,209.09%	0.00%	-64,170.18%
Free Cash Flow to Firm to Interest Expense	-22.81	0.00	-17.26
Operating Cash Flow to Interest Expense	-78.64	0.00	-80.74
Operating Cash Flow Less CapEx to Interest Expense	-78.71	0.00	-80.87
Efficiency Ratios	-	-	-
Asset Turnover	0.69	0.65	0.66
Accounts Receivable Turnover	4.35	4.89	6.37
Inventory Turnover	3.96	3.98	2.94
Fixed Asset Turnover	54.96	44.02	48.88
Accounts Payable Turnover	4.24	4.54	3.32
Days Sales Outstanding (DSO)	83.92	74.62	57.32
Days Inventory Outstanding (DIO)	92.25	91.70	124.12
Days Payable Outstanding (DPO)	86.13	80.37	110.07
Cash Conversion Cycle (CCC)	90.04	85.95	71.37
Capital & Investment Metrics	-	-	-
Invested Capital	-62	-39	-19
Invested Capital Turnover	-3.17	-6.71	225.60
Increase / (Decrease) in Invested Capital	-24	-20	-41
Enterprise Value (EV)	401	225	82
Market Capitalization	415	234	106
Book Value per Share	($0.23)	($0.16)	$0.03
Tangible Book Value per Share	($0.50)	($0.67)	($0.68)
Total Capital	-10	4.10	71
Total Debt	39	35	66
Total Long-Term Debt	39	17	34
Net Debt	-13	-8.24	-24
Capital Expenditures (CapEx)	0.03	0.00	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-7.15	-2.82
Debt-free Net Working Capital (DFNWC)	33	36	88
Net Working Capital (NWC)	33	18	56
Net Nonoperating Expense (NNE)	34	20	38
Net Nonoperating Obligations (NNO)	-13	-8.24	-24
Total Depreciation and Amortization (D&A)	42	42	37
Debt-free, Cash-free Net Working Capital to Revenue	-11.83%	-3.67%	-0.96%
Debt-free Net Working Capital to Revenue	20.55%	18.38%	29.97%
Net Working Capital to Revenue	20.55%	9.39%	19.03%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.28)	($0.51)
Adjusted Weighted Average Basic Shares Outstanding	210.95M	187.47M	182.78M
Adjusted Diluted Earnings per Share	($0.33)	($0.28)	($0.51)
Adjusted Weighted Average Diluted Shares Outstanding	210.95M	187.47M	182.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	236.23M	209.37M	184.25M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-32	-45
Normalized NOPAT Margin	-22.03%	-16.57%	-15.52%
Pre Tax Income Margin	-43.33%	-26.68%	-32.22%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-98.08	0.00	-85.69
NOPAT to Interest Expense	-68.34	0.00	-62.41
EBIT Less CapEx to Interest Expense	-98.15	0.00	-85.81
NOPAT Less CapEx to Interest Expense	-68.40	0.00	-62.54
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-17.26%	-10.98%	-22.58%	-18.49%	-52.13%	-13.69%	-55.39%	0.00%	103.56%	-0.09%
EBITDA Growth	-115.23%	-9.04%	2,520.33%	64.82%	267.90%	91.04%	-100.28%	68.29%	107.69%	8.88%
EBIT Growth	-884.20%	-2.29%	32.50%	40.87%	141.72%	74.05%	-127.97%	57.51%	92.49%	7.44%
NOPAT Growth	-829.37%	4.07%	3.01%	41.65%	140.29%	74.14%	-118.48%	57.04%	92.55%	8.16%
Net Income Growth	-3,826.14%	-38.30%	23.18%	33.08%	132.08%	73.22%	-137.94%	60.28%	97.27%	9.15%
EPS Growth	-1,100.00%	-25.00%	33.33%	40.00%	133.33%	72.41%	-140.00%	57.14%	92.50%	14.71%
Operating Cash Flow Growth	-93.50%	6.59%	-377.38%	-10.80%	95.78%	-121.20%	111.84%	18.88%	12.94%	160.08%
Free Cash Flow Firm Growth	-35.74%	80.40%	-120.30%	179.79%	-43.89%	-154.08%	-7.92%	-475.61%	379.70%	-4.80%
Invested Capital Growth	-60.62%	-6.29%	7.05%	-171.00%	-102.66%	33.29%	-425.07%	272.62%	-188.08%	-339.04%
Revenue Q/Q Growth	24.23%	-14.25%	33.86%	-41.98%	33.65%	-25.42%	40.92%	-65.93%	141.01%	-61.45%
EBITDA Q/Q Growth	40.46%	-234.50%	153.21%	-143.82%	526.31%	-2,885.37%	99.23%	-473.82%	110.38%	-194.21%
EBIT Q/Q Growth	-19.05%	-107.96%	57.03%	-1,190.31%	115.53%	-37.24%	62.35%	-420.03%	90.34%	-247.92%
NOPAT Q/Q Growth	-14.40%	-43.32%	41.58%	-861.49%	115.05%	-44.91%	64.86%	-425.82%	90.34%	-203.55%
Net Income Q/Q Growth	-13.80%	-133.50%	52.28%	-3,038.73%	104.22%	-29.69%	58.43%	-1,308.60%	96.47%	-283.69%
EPS Q/Q Growth	0.00%	-150.00%	55.56%	-1,000.00%	112.50%	-33.33%	60.00%	-400.00%	89.66%	-293.33%
Operating Cash Flow Q/Q Growth	33.29%	33.49%	48.20%	-741.94%	67.80%	-297.49%	120.69%	67.93%	-261.75%	210.26%
Free Cash Flow Firm Q/Q Growth	324.41%	31.36%	-110.49%	297.58%	168.43%	-171.09%	141.26%	-379.56%	-34.04%	21.03%
Invested Capital Q/Q Growth	-35.38%	-30.79%	9.86%	-0.64%	10.41%	-14.37%	-168.85%	387.28%	70.51%	-657.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.20%	62.16%	60.94%	64.41%	66.78%	57.17%	69.34%	49.53%	95.25%	21.42%
EBITDA Margin	-5.13%	-10.70%	6.82%	-17.16%	27.86%	-8.73%	-0.22%	-39.76%	3.62%	-84.13%
Operating Margin	-30.77%	-33.41%	-19.99%	-45.81%	2.44%	-31.00%	-15.96%	-63.98%	-4.15%	-103.47%
EBIT Margin	-34.25%	-35.74%	-14.74%	-45.91%	3.61%	-31.11%	-16.90%	-63.28%	-4.15%	-103.47%
Profit (Net Income) Margin	-49.04%	-53.54%	-19.66%	-55.16%	1.09%	-34.46%	-19.82%	-67.18%	-1.63%	-111.05%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	578.18%	97.89%
Interest Burden Percent	143.18%	149.79%	133.41%	120.14%	30.13%	110.78%	117.23%	106.17%	6.78%	109.64%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-752.14%	0.00%	0.00%	0.00%	-1,286.39%	-654.77%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-753.07%	0.00%	0.00%	0.00%	-1,286.96%	-658.69%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	760.53%	0.00%	0.00%	0.00%	1,296.54%	637.13%	0.00%
Return on Equity (ROE)	174.03%	102.41%	133.56%	8.39%	409.60%	425.87%	12.35%	10.15%	-17.64%	-214.80%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-217.45%	0.00%	0.00%
Operating Return on Assets (OROA)	-23.73%	-27.47%	-10.85%	-33.95%	2.35%	-23.72%	-11.33%	-51.15%	-2.74%	-46.40%
Return on Assets (ROA)	-33.98%	-41.14%	-14.48%	-40.78%	0.71%	-26.28%	-13.28%	-54.30%	-1.07%	-49.79%
Return on Common Equity (ROCE)	174.03%	102.41%	133.56%	8.39%	409.60%	425.87%	12.35%	10.15%	-17.64%	-214.80%
Return on Equity Simple (ROE_SIMPLE)	0.00%	91.25%	119.82%	157.88%	0.00%	138.11%	350.85%	279.38%	0.00%	-1,170.72%
Net Operating Profit after Tax (NOPAT)	-10	-8.75	-6.11	-10	1.37	-9.13	-6.30	-18	-3.41	-35
NOPAT Margin	-21.54%	-23.39%	-13.99%	-32.06%	2.44%	-21.70%	-11.17%	-44.79%	-2.90%	-72.43%
Net Nonoperating Expense Percent (NNEP)	-119.42%	5,374.05%	-39.42%	0.93%	-4.66%	-12.97%	0.65%	0.57%	3.91%	-19.93%
Return On Investment Capital (ROIC_SIMPLE)	95.45%	-	-	-	33.50%	-	-	-	-	-
Cost of Revenue to Revenue	43.80%	37.84%	39.06%	35.59%	33.22%	42.83%	30.66%	50.47%	4.75%	78.58%
SG&A Expenses to Revenue	59.52%	70.85%	61.67%	78.01%	45.26%	54.01%	47.96%	62.62%	25.47%	65.46%
R&D to Revenue	25.35%	22.68%	17.52%	29.84%	17.56%	31.70%	35.83%	49.21%	64.67%	57.54%
Operating Expenses to Revenue	86.97%	95.58%	80.93%	110.22%	64.34%	88.17%	85.30%	113.52%	92.50%	124.89%
Earnings before Interest and Taxes (EBIT)	-16	-13	-6.43	-15	2.03	-13	-9.53	-25	-4.87	-50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.38	-4.00	2.98	-5.60	16	-3.67	-0.12	-16	4.26	-41
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.30	4.20
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.59	1.63	1.23	2.05	1.20	0.84	0.65	0.31	0.36	0.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.88	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.51	1.66	1.22	1.98	1.16	0.82	0.61	0.31	0.28	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	41.43	29.75	92.01	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	5.37	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.79	-0.76	-1.13	-1.11	-1.13	-1.08	-1.58	0.00	12.63	4.76
Long-Term Debt to Equity	-0.79	-0.76	-1.13	-1.11	-0.56	-0.88	-0.69	0.00	6.52	0.00
Financial Leverage	0.27	0.00	0.21	-1.01	1.29	3.24	-0.98	-1.01	-0.97	-1.25
Leverage Ratio	-5.80	-4.92	-7.83	-0.31	-23.58	-26.24	-0.51	-0.26	11.17	6.88
Compound Leverage Factor	-8.30	-7.37	-10.44	-0.38	-7.10	-29.07	-0.60	-0.28	0.76	7.54
Debt to Total Capital	-368.79%	-318.38%	889.20%	1,044.16%	846.13%	1,335.41%	270.97%	0.00%	92.67%	82.64%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	426.93%	250.71%	153.07%	0.00%	44.88%	82.64%
Long-Term Debt to Total Capital	-368.79%	-318.38%	889.20%	1,044.16%	419.20%	1,084.71%	117.90%	0.00%	47.79%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	468.79%	418.38%	-789.20%	-944.16%	-746.13%	-1,235.41%	-170.97%	100.00%	7.33%	17.36%
Debt to EBITDA	-4.30	5.64	5.33	7.47	-8.57	-2.81	-0.81	0.00	-1.64	-0.64
Net Debt to EBITDA	1.46	0.64	-0.21	-2.93	2.04	0.26	0.21	0.00	0.61	0.76
Long-Term Debt to EBITDA	-4.30	5.64	5.33	7.47	-4.25	-2.28	-0.35	0.00	-0.85	0.00
Debt to NOPAT	-1.10	-1.57	-1.54	-1.21	-1.07	-1.16	-0.68	0.00	-1.17	-0.67
Net Debt to NOPAT	0.37	-0.18	0.06	0.47	0.25	0.11	0.18	0.00	0.43	0.80
Long-Term Debt to NOPAT	-1.10	-1.57	-1.54	-1.21	-0.53	-0.94	-0.29	0.00	-0.60	0.00
Altman Z-Score	-9.06	-9.74	-9.17	-8.33	-7.88	-8.06	-7.40	-6.66	-4.98	-4.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.41	1.52	1.04	1.70	1.18	1.38	1.28	1.38	1.43	1.26
Quick Ratio	1.07	1.01	0.65	1.03	0.82	0.87	0.79	0.21	1.01	0.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	14	-6.03	-8.78	84	21	-31	43	-105	38	57
Operating Cash Flow to CapEx	-223,300.00%	-334,750.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	161.81	0.00	0.00	0.00	0.00	0.00	62.75
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-37.59	0.00	0.00	0.00	0.00	0.00	37.31
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-37.59	0.00	0.00	0.00	0.00	0.00	37.31
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.69	0.77	0.74	0.74	0.65	0.76	0.67	0.81	0.66	0.45
Accounts Receivable Turnover	4.35	6.20	7.07	8.26	4.89	11.20	5.17	7.91	6.37	6.40
Inventory Turnover	3.96	3.16	2.92	2.85	3.98	2.09	2.66	2.69	2.94	3.46
Fixed Asset Turnover	54.96	51.82	47.72	0.00	44.02	53.05	0.00	0.00	48.88	36.32
Accounts Payable Turnover	4.24	5.46	5.97	0.00	4.54	4.25	0.00	0.00	3.32	5.26
Days Sales Outstanding (DSO)	83.92	58.83	51.60	44.21	74.62	32.59	70.62	46.16	57.32	57.07
Days Inventory Outstanding (DIO)	92.25	115.58	125.09	127.88	91.70	174.78	137.16	135.81	124.12	105.44
Days Payable Outstanding (DPO)	86.13	66.89	61.13	0.00	80.37	85.91	0.00	0.00	110.07	69.39
Cash Conversion Cycle (CCC)	90.04	107.52	115.56	172.09	85.95	121.46	207.78	181.97	71.37	93.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-62	-46	-35	-39	-39	-43	-38	55	-19	-65
Invested Capital Turnover	-3.17	-3.80	-4.77	23.46	-6.71	-4.72	-20.01	28.72	225.60	-12.32
Increase / (Decrease) in Invested Capital	-24	-2.73	2.67	-94	-20	22	-50	87	-41	-92
Enterprise Value (EV)	401	282	212	371	225	211	159	103	82	-21
Market Capitalization	415	278	214	383	234	215	170	103	106	58
Book Value per Share	($0.23)	($0.24)	($0.16)	($0.13)	($0.16)	($0.21)	($0.14)	($8.60)	$0.03	$0.08
Tangible Book Value per Share	($0.50)	($0.56)	($0.53)	($0.54)	($0.67)	($0.76)	($0.75)	($8.92)	($0.68)	($0.67)
Total Capital	-10	-12	4.28	2.89	4.10	3.19	16	-1,584	71	80
Total Debt	39	38	38	30	35	43	42	0.00	66	66
Total Long-Term Debt	39	38	38	30	17	35	18	0.00	34	0.00
Net Debt	-13	4.34	-1.47	-12	-8.24	-3.92	-11	0.00	-24	-79
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	0.39	-35	4.50	-7.15	-8.63	-3.31	33	-2.82	-29
Debt-free Net Working Capital (DFNWC)	33	34	4.80	46	36	38	50	33	88	115
Net Working Capital (NWC)	33	34	4.80	46	18	30	26	33	56	50
Net Nonoperating Expense (NNE)	13	11	2.47	7.53	0.76	5.36	4.87	8.96	-1.50	19
Net Nonoperating Obligations (NNO)	-13	4.34	-1.47	-12	-8.24	-3.92	-11	1,639	-24	-79
Total Depreciation and Amortization (D&A)	14	9.37	9.41	9.38	14	9.41	9.41	9.41	9.12	9.42
Debt-free, Cash-free Net Working Capital to Revenue	-11.83%	0.23%	-19.89%	2.40%	-3.67%	-3.37%	-1.26%	9.97%	-0.96%	-12.57%
Debt-free Net Working Capital to Revenue	20.55%	20.26%	2.75%	24.81%	18.38%	14.81%	19.15%	9.97%	29.97%	49.62%
Net Working Capital to Revenue	20.55%	20.26%	2.75%	24.81%	9.39%	11.69%	10.01%	9.97%	19.03%	21.29%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	($0.10)	($0.04)	($0.09)	$0.01	($0.08)	$0.00	$0.00	($0.04)	($0.28)
Adjusted Weighted Average Basic Shares Outstanding	210.95M	210.35M	209.71M	204.96M	187.47M	188.31M	0.00	0.00	182.78M	183.88M
Adjusted Diluted Earnings per Share	($0.10)	($0.10)	($0.04)	($0.09)	$0.01	($0.08)	$0.00	$0.00	($0.03)	($0.28)
Adjusted Weighted Average Diluted Shares Outstanding	210.95M	210.35M	209.71M	204.96M	187.47M	188.31M	0.00	0.00	182.78M	183.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	236.23M	218.18M	210.29M	209.60M	209.37M	188.39M	0.00	0.00	184.25M	183.96M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-8.75	-6.11	-10	0.96	-9.01	-6.36	-18	-2.55	-35
Normalized NOPAT Margin	-21.54%	-23.39%	-13.99%	-31.94%	1.71%	-21.42%	-11.29%	-44.60%	-2.17%	-72.17%
Pre Tax Income Margin	-49.04%	-53.54%	-19.66%	-55.16%	1.09%	-34.46%	-19.82%	-67.18%	-0.28%	-113.44%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-28.96	0.00	0.00	0.00	0.00	0.00	-55.63
NOPAT to Interest Expense	0.00	0.00	0.00	-20.22	0.00	0.00	0.00	0.00	0.00	-38.94
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-28.96	0.00	0.00	0.00	0.00	0.00	-55.63
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-20.22	0.00	0.00	0.00	0.00	0.00	-38.94
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Akebia Therapeutics' Financials

When does Akebia Therapeutics's financial year end?

According to the most recent income statement we have on file, Akebia Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Akebia Therapeutics' net income changed over the last 2 years?

Akebia Therapeutics' net income appears to be on a downward trend, with a most recent value of -$69.41 million in 2024, falling from -$94.23 million in 2022. The previous period was -$51.93 million in 2023. Check out Akebia Therapeutics' forecast to explore projected trends and price targets.

What is Akebia Therapeutics's operating income?

Akebia Therapeutics's total operating income in 2024 was -$50.47 million, based on the following breakdown:

Total Gross Profit: $97.00 million
Total Operating Expenses: $147.48 million

How has Akebia Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Akebia Therapeutics' total revenue changed from $292.48 million in 2022 to $160.18 million in 2024, a change of -45.2%.

How much debt does Akebia Therapeutics have?

Akebia Therapeutics' total liabilities were at $269.86 million at the end of 2024, a 0.9% decrease from 2023, and a 23.1% decrease since 2022.

How much cash does Akebia Therapeutics have?

In the past 2 years, Akebia Therapeutics' cash and equivalents has ranged from $42.93 million in 2023 to $90.47 million in 2022, and is currently $51.87 million as of their latest financial filing in 2024.

How has Akebia Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Akebia Therapeutics' book value per share changed from 0.03 in 2022 to -0.23 in 2024, a change of -893.7%.

Related Companies

This page (NASDAQ:AKBA) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Financials

Frequently Asked Questions About Akebia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Financials

Annual Income Statements for Akebia Therapeutics

Quarterly Income Statements for Akebia Therapeutics

Annual Cash Flow Statements for Akebia Therapeutics

Quarterly Cash Flow Statements for Akebia Therapeutics

Annual Balance Sheets for Akebia Therapeutics

Quarterly Balance Sheets for Akebia Therapeutics

Annual Metrics And Ratios for Akebia Therapeutics

Quarterly Metrics And Ratios for Akebia Therapeutics

Frequently Asked Questions About Akebia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools